Latest Regulatory Updates News

AVITA Medical posted robust Q2 2026 results with 18% revenue growth, driven by RECELL and supported by Cohealyx and PermeaDerm, and now expects to reach cash flow breakeven by year-end.

Novatti Group Limited delivered a 5% quarter-on-quarter revenue increase to $7.6 million in Q4 FY26, driven by its Payments AU/NZ segment's strong 8% revenue and 26% margin growth. The company achieved positive EBITDA of $0.3 million, boosted by a 95% jump in Payments AU/NZ EBITDA to $0.9 million.

Predictive Discovery reported a 33% increase in gold production to 64,026 ounces in Q2 2026, driven by Kiniero’s operational ramp-up and advancing development at the Bankan project.

Solis Minerals has secured a strategic lithium asset in Brazil's Araçuaí–Salinas Lithium Valley and initiated drilling at Mandacaru, while advancing copper projects in Peru with fresh capital backing.

Whitehaven Coal delivered a robust finish to FY26, hitting top-end guidance for production and sales while improving safety and reducing costs.

AFT Pharmaceuticals has received tentative US FDA approval for its Scomara cream to treat Facial Angiofibromas in Tuberous Sclerosis, but US commercialisation is postponed until 2029 due to orphan drug exclusivity. The approval bolsters regulatory prospects in other key markets where AFT anticipates competitive advantages.

Salt Listed Funds released its 2026 annual report highlighting governance changes, investment policy updates including Treasury Units and Carbon-Related Businesses, and a notable decline in the Carbon Fund’s unit price over the year.

Diamond Infraco has extended its takeover offer for Atlas Arteria to 25 June 2026, waiving several key conditions and adjusting the timeline for regulatory updates.

OncoSil Medical has cleared a major regulatory hurdle as its Humanitarian Device Exemption application nears FDA approval, while its TRIPP-FFX trial shows promising results combining OncoSil with standard chemotherapy for pancreatic cancer.

AuKing Mining expands its footprint at the Tundulu Rare Earths Project in Malawi through a structured earn-in agreement and a fresh airborne survey revealing a larger carbonatite system with multiple new drill targets.

The Therapeutic Goods Administration has broadened the range of clinicians eligible to participate in psychedelic-assisted psychotherapy, a move set to speed up recruitment and improve patient access across Emyria’s national Empax network.

ANZ Group Holdings Limited posted a 14% rise in cash profit for 1H26 to AUD 3.78 billion, driven by cost reductions and steady revenue, while declaring an 83-cent interim dividend with 75% franking.